{"id":18319,"date":"2017-03-16T14:00:34","date_gmt":"2017-03-16T14:00:34","guid":{"rendered":"https:\/\/ipo.org\/?p=18319"},"modified":"2017-03-17T15:25:50","modified_gmt":"2017-03-17T15:25:50","slug":"divided-infringement-life-sciences-patent-prosecution-perspective","status":"publish","type":"post","link":"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/","title":{"rendered":"Divided Infringement in the Life Sciences: Patent Prosecution Perspective"},"content":{"rendered":"<p><span>With the Federal Circuit decision earlier this year in\u00a0<em>Eli Lilly v. Teva Parenteral,\u00a0<\/em>the reach of divided infringement into the life sciences left the realm of the hypothetical.\u00a0<em>Akamai v. Limelight<\/em> and other prior cases about divided infringement involved software and the Internet, but the\u00a0<em>Lilly\u00a0<\/em>case involved a medical method of treatment. The case is also the first Federal Circuit decision to affirm a finding of divided infringement using the new standard for &#8220;direct or control&#8221; established by the en banc Federal Circuit in August 2015. Under that standard, an infringer can be found guilty of infringement, even if one did not perform all steps of a patented method. In addition to exerting control through traditional means, an infringer can now be held liable when one &#8220;conditions participation in an activity or receipt of a benefit upon performance of a step or steps of a patented method and establishes the manner or timing of that performance.&#8221; The relationship between doctor and patient is discussed in this context in the\u00a0<em>Lilly\u00a0<\/em>opinion.<\/span><\/p>\n<p><span>Our panel, which includes an in-house patent counsel at a drug company and two patent prosecutors, will analyze\u00a0<em>Lilly<\/em>, and extract principles that can be used to guide patent claim drafting in such fields as personalized medicine and companion diagnostics, measuring the efficacy of treatment through biomarkers, and methods involving pretreatment. The panelists will also consider the interplay of factors unique to the drug industry, such as the role of the FDA label.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>With the Federal Circuit decision earlier this year in\u00a0Eli Lilly  [&#8230;]<\/p>\n","protected":false},"author":72,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-18319","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Divided Infringement in the Life Sciences: Patent Prosecution Perspective - Intellectual Property Owners Association<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Divided Infringement in the Life Sciences: Patent Prosecution Perspective - Intellectual Property Owners Association\" \/>\n<meta property=\"og:description\" content=\"With the Federal Circuit decision earlier this year in\u00a0Eli Lilly [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/\" \/>\n<meta property=\"og:site_name\" content=\"Intellectual Property Owners Association\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/IPOAssociation\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-03-16T14:00:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-03-17T15:25:50+00:00\" \/>\n<meta name=\"author\" content=\"Michael Marion\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ipo\" \/>\n<meta name=\"twitter:site\" content=\"@ipo\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Marion\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/divided-infringement-life-sciences-patent-prosecution-perspective\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/divided-infringement-life-sciences-patent-prosecution-perspective\\\/\"},\"author\":{\"name\":\"Michael Marion\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/person\\\/b2b29aa393fbb03aea9dab179a9c936e\"},\"headline\":\"Divided Infringement in the Life Sciences: Patent Prosecution Perspective\",\"datePublished\":\"2017-03-16T14:00:34+00:00\",\"dateModified\":\"2017-03-17T15:25:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/divided-infringement-life-sciences-patent-prosecution-perspective\\\/\"},\"wordCount\":254,\"publisher\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/divided-infringement-life-sciences-patent-prosecution-perspective\\\/\",\"url\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/divided-infringement-life-sciences-patent-prosecution-perspective\\\/\",\"name\":\"Divided Infringement in the Life Sciences: Patent Prosecution Perspective - Intellectual Property Owners Association\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#website\"},\"datePublished\":\"2017-03-16T14:00:34+00:00\",\"dateModified\":\"2017-03-17T15:25:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/divided-infringement-life-sciences-patent-prosecution-perspective\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ipo.org\\\/index.php\\\/divided-infringement-life-sciences-patent-prosecution-perspective\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/divided-infringement-life-sciences-patent-prosecution-perspective\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ipo.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Divided Infringement in the Life Sciences: Patent Prosecution Perspective\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#website\",\"url\":\"https:\\\/\\\/ipo.org\\\/\",\"name\":\"Intellectual Property Owners Association\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ipo.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\",\"name\":\"Intellectual Property Owners Association\",\"url\":\"https:\\\/\\\/ipo.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ipo.org\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/ipo_logo.png\",\"contentUrl\":\"https:\\\/\\\/ipo.org\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/ipo_logo.png\",\"width\":570,\"height\":226,\"caption\":\"Intellectual Property Owners Association\"},\"image\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/IPOAssociation\\\/\",\"https:\\\/\\\/x.com\\\/ipo\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ipoassociation\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/person\\\/b2b29aa393fbb03aea9dab179a9c936e\",\"name\":\"Michael Marion\",\"description\":\"1819\",\"sameAs\":[\"https:\\\/\\\/ipo.org\"],\"url\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/author\\\/michael-309\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Divided Infringement in the Life Sciences: Patent Prosecution Perspective - Intellectual Property Owners Association","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/","og_locale":"en_US","og_type":"article","og_title":"Divided Infringement in the Life Sciences: Patent Prosecution Perspective - Intellectual Property Owners Association","og_description":"With the Federal Circuit decision earlier this year in\u00a0Eli Lilly [...]","og_url":"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/","og_site_name":"Intellectual Property Owners Association","article_publisher":"https:\/\/www.facebook.com\/IPOAssociation\/","article_published_time":"2017-03-16T14:00:34+00:00","article_modified_time":"2017-03-17T15:25:50+00:00","author":"Michael Marion","twitter_card":"summary_large_image","twitter_creator":"@ipo","twitter_site":"@ipo","twitter_misc":{"Written by":"Michael Marion","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/#article","isPartOf":{"@id":"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/"},"author":{"name":"Michael Marion","@id":"https:\/\/ipo.org\/#\/schema\/person\/b2b29aa393fbb03aea9dab179a9c936e"},"headline":"Divided Infringement in the Life Sciences: Patent Prosecution Perspective","datePublished":"2017-03-16T14:00:34+00:00","dateModified":"2017-03-17T15:25:50+00:00","mainEntityOfPage":{"@id":"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/"},"wordCount":254,"publisher":{"@id":"https:\/\/ipo.org\/#organization"},"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/","url":"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/","name":"Divided Infringement in the Life Sciences: Patent Prosecution Perspective - Intellectual Property Owners Association","isPartOf":{"@id":"https:\/\/ipo.org\/#website"},"datePublished":"2017-03-16T14:00:34+00:00","dateModified":"2017-03-17T15:25:50+00:00","breadcrumb":{"@id":"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ipo.org\/index.php\/divided-infringement-life-sciences-patent-prosecution-perspective\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipo.org\/"},{"@type":"ListItem","position":2,"name":"Divided Infringement in the Life Sciences: Patent Prosecution Perspective"}]},{"@type":"WebSite","@id":"https:\/\/ipo.org\/#website","url":"https:\/\/ipo.org\/","name":"Intellectual Property Owners Association","description":"","publisher":{"@id":"https:\/\/ipo.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipo.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ipo.org\/#organization","name":"Intellectual Property Owners Association","url":"https:\/\/ipo.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipo.org\/#\/schema\/logo\/image\/","url":"https:\/\/ipo.org\/wp-content\/uploads\/2019\/06\/ipo_logo.png","contentUrl":"https:\/\/ipo.org\/wp-content\/uploads\/2019\/06\/ipo_logo.png","width":570,"height":226,"caption":"Intellectual Property Owners Association"},"image":{"@id":"https:\/\/ipo.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/IPOAssociation\/","https:\/\/x.com\/ipo","https:\/\/www.linkedin.com\/company\/ipoassociation\/"]},{"@type":"Person","@id":"https:\/\/ipo.org\/#\/schema\/person\/b2b29aa393fbb03aea9dab179a9c936e","name":"Michael Marion","description":"1819","sameAs":["https:\/\/ipo.org"],"url":"https:\/\/ipo.org\/index.php\/author\/michael-309\/"}]}},"_links":{"self":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/18319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/users\/72"}],"replies":[{"embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/comments?post=18319"}],"version-history":[{"count":1,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/18319\/revisions"}],"predecessor-version":[{"id":18320,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/18319\/revisions\/18320"}],"wp:attachment":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/media?parent=18319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/categories?post=18319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/tags?post=18319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}